CA2501253A1 - Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments - Google Patents

Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments Download PDF

Info

Publication number: CA2501253A1
Authority: CA; Canada
Prior art keywords: drug; gene; act; variant allele; sample
Prior art date: 2005-03-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002501253A

Other languages

English (en)

Inventor

Juergen Brockmoeller

Lorenz Truemper

Gerd Hasenfuss

Leszek Wojnowski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-18

Filing date

2005-03-18

Publication date

2006-09-18

2005-03-18 Application filed by Individual filed Critical Individual

2005-03-18 Priority to CA002501253A priority Critical patent/CA2501253A1/fr

2006-09-18 Publication of CA2501253A1 publication Critical patent/CA2501253A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 135
238000002651 drug therapy Methods 0.000 title description 4
206010061623 Adverse drug reaction Diseases 0.000 title description 2
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 title description 2
239000003814 drug Substances 0.000 claims abstract description 109
229940079593 drug Drugs 0.000 claims abstract description 94
206010048610 Cardiotoxicity Diseases 0.000 claims abstract description 40
231100000259 cardiotoxicity Toxicity 0.000 claims abstract description 40
208000020446 Cardiac disease Diseases 0.000 claims abstract description 18
208000019622 heart disease Diseases 0.000 claims abstract description 18
208000034826 Genetic Predisposition to Disease Diseases 0.000 claims abstract description 11
108090000623 proteins and genes Proteins 0.000 claims description 133
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 98
108700028369 Alleles Proteins 0.000 claims description 84
239000000523 sample Substances 0.000 claims description 54
229960004679 doxorubicin Drugs 0.000 claims description 45
229940045799 anthracyclines and related substance Drugs 0.000 claims description 42
238000011282 treatment Methods 0.000 claims description 36
239000003642 reactive oxygen metabolite Substances 0.000 claims description 35
102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 claims description 33
108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 claims description 33
230000001154 acute effect Effects 0.000 claims description 32
239000008194 pharmaceutical composition Substances 0.000 claims description 32
108010066052 multidrug resistance-associated protein 1 Proteins 0.000 claims description 30
239000002773 nucleotide Substances 0.000 claims description 29
125000003729 nucleotide group Chemical group 0.000 claims description 29
102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims description 28
230000001684 chronic effect Effects 0.000 claims description 25
102000004169 proteins and genes Human genes 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
108010002998 NADPH Oxidases Proteins 0.000 claims description 22
102000004722 NADPH Oxidases Human genes 0.000 claims description 22
201000010099 disease Diseases 0.000 claims description 22
206010028980 Neoplasm Diseases 0.000 claims description 20
230000032895 transmembrane transport Effects 0.000 claims description 19
108091034117 Oligonucleotide Proteins 0.000 claims description 18
102100025620 Cytochrome b-245 light chain Human genes 0.000 claims description 17
238000003205 genotyping method Methods 0.000 claims description 17
101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 claims description 15
101001110313 Homo sapiens Ras-related C3 botulinum toxin substrate 2 Proteins 0.000 claims description 15
102100022129 Ras-related C3 botulinum toxin substrate 2 Human genes 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 15
238000009396 hybridization Methods 0.000 claims description 15
108010086154 neutrophil cytosol factor 40K Proteins 0.000 claims description 15
150000007523 nucleic acids Chemical class 0.000 claims description 15
206010019280 Heart failures Diseases 0.000 claims description 14
102100023617 Neutrophil cytosol factor 4 Human genes 0.000 claims description 14
206010003119 arrhythmia Diseases 0.000 claims description 14
230000006793 arrhythmia Effects 0.000 claims description 14
238000003556 assay Methods 0.000 claims description 14
108091033319 polynucleotide Proteins 0.000 claims description 14
101000856723 Homo sapiens Cytochrome b-245 light chain Proteins 0.000 claims description 13
238000001514 detection method Methods 0.000 claims description 13
230000004064 dysfunction Effects 0.000 claims description 13
102000039446 nucleic acids Human genes 0.000 claims description 13
108020004707 nucleic acids Proteins 0.000 claims description 13
102000040430 polynucleotide Human genes 0.000 claims description 13
239000002157 polynucleotide Substances 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
206010007559 Cardiac failure congestive Diseases 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 9
231100000500 noncardiotoxic Toxicity 0.000 claims description 8
230000003321 amplification Effects 0.000 claims description 7
229940034982 antineoplastic agent Drugs 0.000 claims description 7
238000012217 deletion Methods 0.000 claims description 7
230000037430 deletion Effects 0.000 claims description 7
238000003199 nucleic acid amplification method Methods 0.000 claims description 7
238000012163 sequencing technique Methods 0.000 claims description 7
239000000556 agonist Substances 0.000 claims description 6
238000006467 substitution reaction Methods 0.000 claims description 6
239000012190 activator Substances 0.000 claims description 5
230000004071 biological effect Effects 0.000 claims description 5
238000001802 infusion Methods 0.000 claims description 5
230000004952 protein activity Effects 0.000 claims description 5
102220041674 rs63751069 Human genes 0.000 claims description 5
238000002347 injection Methods 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
101150009724 CYBA gene Proteins 0.000 claims description 3
101100404257 Homo sapiens NCF4 gene Proteins 0.000 claims description 3
101150042167 NCF4 gene Proteins 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
239000000872 buffer Substances 0.000 claims description 3
239000003599 detergent Substances 0.000 claims description 3
230000002255 enzymatic effect Effects 0.000 claims description 3
238000007834 ligase chain reaction Methods 0.000 claims description 3
102200087998 rs8187710 Human genes 0.000 claims description 3
210000003296 saliva Anatomy 0.000 claims description 3
108091026890 Coding region Proteins 0.000 claims description 2
108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
101150017517 MRP1 gene Proteins 0.000 claims description 2
101150081792 MRP2 gene Proteins 0.000 claims description 2
101150115387 Rac2 gene Proteins 0.000 claims description 2
230000029087 digestion Effects 0.000 claims description 2
102000002568 Multienzyme Complexes Human genes 0.000 claims 2
108010093369 Multienzyme Complexes Proteins 0.000 claims 2
102000014842 Multidrug resistance proteins Human genes 0.000 claims 1
108050005144 Multidrug resistance proteins Proteins 0.000 claims 1
102200087915 rs17222723 Human genes 0.000 claims 1
238000002405 diagnostic procedure Methods 0.000 abstract description 5
230000000694 effects Effects 0.000 description 30
238000002560 therapeutic procedure Methods 0.000 description 28
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 27
229960004397 cyclophosphamide Drugs 0.000 description 27
108020004414 DNA Proteins 0.000 description 26
229960004528 vincristine Drugs 0.000 description 25
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 25
229960004618 prednisone Drugs 0.000 description 23
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 23
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 22
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 22
229960005420 etoposide Drugs 0.000 description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
238000004458 analytical method Methods 0.000 description 19
210000004027 cell Anatomy 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
230000002068 genetic effect Effects 0.000 description 17
108010006654 Bleomycin Proteins 0.000 description 16
229960001561 bleomycin Drugs 0.000 description 16
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 16
239000000126 substance Substances 0.000 description 16
230000014509 gene expression Effects 0.000 description 15
102000054765 polymorphisms of proteins Human genes 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
238000009472 formulation Methods 0.000 description 12
238000003752 polymerase chain reaction Methods 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
229920001184 polypeptide Polymers 0.000 description 11
230000001105 regulatory effect Effects 0.000 description 11
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 10
150000001413 amino acids Chemical group 0.000 description 10
238000002512 chemotherapy Methods 0.000 description 10
239000007787 solid Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
125000003275 alpha amino acid group Chemical group 0.000 description 9
239000000203 mixture Substances 0.000 description 9
230000035772 mutation Effects 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
229940124597 therapeutic agent Drugs 0.000 description 9
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
229960001904 epirubicin Drugs 0.000 description 8
239000012634 fragment Substances 0.000 description 8
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 8
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 7
230000000747 cardiac effect Effects 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
229960001156 mitoxantrone Drugs 0.000 description 7
230000009467 reduction Effects 0.000 description 7
239000000758 substrate Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
230000032258 transport Effects 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
108010078791 Carrier Proteins Proteins 0.000 description 6
102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 6
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
229960000485 methotrexate Drugs 0.000 description 6
238000010369 molecular cloning Methods 0.000 description 6
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 6
101710190086 Cytochrome b-245 light chain Proteins 0.000 description 5
108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 5
108091092195 Intron Proteins 0.000 description 5
238000007792 addition Methods 0.000 description 5
239000000969 carrier Substances 0.000 description 5
IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
229960005205 prednisolone Drugs 0.000 description 5
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
238000012552 review Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 5
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 4
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
108700024394 Exon Proteins 0.000 description 4
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 4
102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
230000004075 alteration Effects 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
229960000684 cytarabine Drugs 0.000 description 4
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
229960000908 idarubicin Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000007477 logistic regression Methods 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
229960004584 methylprednisolone Drugs 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
229960000624 procarbazine Drugs 0.000 description 4
230000008569 process Effects 0.000 description 4
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
229960003048 vinblastine Drugs 0.000 description 4
244000105975 Antidesma platyphyllum Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
108091092878 Microsatellite Proteins 0.000 description 3
KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
229940009456 adriamycin Drugs 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000003491 array Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
235000009424 haa Nutrition 0.000 description 3
230000036541 health Effects 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
230000003340 mental effect Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
238000007899 nucleic acid hybridization Methods 0.000 description 3
230000007310 pathophysiology Effects 0.000 description 3
230000002974 pharmacogenomic effect Effects 0.000 description 3
229960001221 pirarubicin Drugs 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000004904 shortening Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
239000013598 vector Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 2
102000017910 Adrenergic receptor Human genes 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
206010007556 Cardiac failure acute Diseases 0.000 description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
238000000729 Fisher's exact test Methods 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000003683 cardiac damage Effects 0.000 description 2
231100000457 cardiotoxic Toxicity 0.000 description 2
230000001451 cardiotoxic effect Effects 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960004630 chlorambucil Drugs 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
229940124301 concurrent medication Drugs 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
-1 cyanomorpholino DOX Chemical compound 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
238000013461 design Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
238000002565 electrocardiography Methods 0.000 description 2
230000009088 enzymatic function Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
229940063725 leukeran Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
229940087732 matulane Drugs 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000037230 mobility Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
208000008494 pericarditis Diseases 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
229960004982 vinblastine sulfate Drugs 0.000 description 2
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
229960004355 vindesine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
102000017904 ADRA2C Human genes 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
206010063081 Acute left ventricular failure Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
108700001611 CEOP-B protocol Proteins 0.000 description 1
108700020517 CHOP-B protocol Proteins 0.000 description 1
101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108010002947 Connectin Proteins 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
102400000686 Endothelin-1 Human genes 0.000 description 1
101800004490 Endothelin-1 Proteins 0.000 description 1
206010016803 Fluid overload Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010048723 Multiple-drug resistance Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108700013460 PMitCEBO protocol Proteins 0.000 description 1
108700034306 PROMACE-CytaBOM protocol Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
238000010357 RNA editing Methods 0.000 description 1
230000026279 RNA modification Effects 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102100026260 Titin Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
231100001259 acute cardiotoxicity Toxicity 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000012093 association test Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000013475 authorization Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
238000002592 echocardiography Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940087477 ellence Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
YBGRCYCEEDOTDH-JYNQXTMKSA-N evap protocol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 YBGRCYCEEDOTDH-JYNQXTMKSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000005021 gait Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
238000012203 high throughput assay Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940099279 idamycin Drugs 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
201000011614 malignant glioma Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
238000001690 micro-dialysis Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000000491 multivariate analysis Methods 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000030147 nuclear export Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000016833 positive regulation of signal transduction Effects 0.000 description 1
229960004694 prednimustine Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
229960001586 procarbazine hydrochloride Drugs 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
108090000446 ribonuclease T(2) Proteins 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
102200043059 rs60782127 Human genes 0.000 description 1
238000007790 scraping Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229960002110 vincristine sulfate Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Microbiology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Pathology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA002501253A 2005-03-18 2005-03-18 Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments Abandoned CA2501253A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002501253A CA2501253A1 (fr)	2005-03-18	2005-03-18	Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002501253A CA2501253A1 (fr)	2005-03-18	2005-03-18	Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments

Publications (1)

Publication Number	Publication Date
CA2501253A1 true CA2501253A1 (fr)	2006-09-18

Family

ID=37054271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002501253A Abandoned CA2501253A1 (fr)	2005-03-18	2005-03-18	Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments

Country Status (1)

Country	Link
CA (1)	CA2501253A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008058394A1 (fr) *	2006-11-15	2008-05-22	The University Of British Columbia	Polymorphismes prédictifs de la cardiotoxicité induite par l'anthracycline
CN106987906A (zh) *	2017-05-15	2017-07-28	重庆市肿瘤研究所	肿瘤治疗心脏毒性预测基因突变检测文库的构建方法
CN121011356A (zh) *	2025-10-27	2025-11-25	四川省医学科学院·四川省人民医院	基于多模态数据融合的乳腺癌心脏毒性风险预测系统

2005
- 2005-03-18 CA CA002501253A patent/CA2501253A1/fr not_active Abandoned

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008058394A1 (fr) *	2006-11-15	2008-05-22	The University Of British Columbia	Polymorphismes prédictifs de la cardiotoxicité induite par l'anthracycline
EP2312024A1 (fr) *	2006-11-15	2011-04-20	The University Of British Columbia	Polymorphismes prédictifs de la cardiotoxicite induite par l'anthracyclin
EP2527501A1 (fr) *	2006-11-15	2012-11-28	The University Of British Columbia	Polymorphismes prédictifs de la cardiotoxicité induite par l'anthracyclin
AU2007321678B2 (en) *	2006-11-15	2014-03-20	The University Of British Columbia	Polymorphisms predictive of anthracycline-induced cardiotoxicity
CN106987906A (zh) *	2017-05-15	2017-07-28	重庆市肿瘤研究所	肿瘤治疗心脏毒性预测基因突变检测文库的构建方法
CN121011356A (zh) *	2025-10-27	2025-11-25	四川省医学科学院·四川省人民医院	基于多模态数据融合的乳腺癌心脏毒性风险预测系统
CN121011356B (zh) *	2025-10-27	2025-12-23	四川省医学科学院·四川省人民医院	基于多模态数据融合的乳腺癌心脏毒性风险预测系统

Legal Events

Date	Code	Title	Description
2009-03-18	FZDE	Dead

Publication	Publication Date	Title
US20110236885A1 (en)	2011-09-29	Genetic Variants Predicting Warfarin Sensitivity
EP1978107A1 (fr)	2008-10-08	Polymorphismes de gènes FTO associés à l'obésité et/ou les diabètes de type II
US20070298426A1 (en)	2007-12-27	Warfarin dosage prediction
WO2006063704A2 (fr)	2006-06-22	Polymorphisme a simple nucleotide (snp)
EP1673473A1 (fr)	2006-06-28	Utilisation de polymorphismes genetiques compatibles avec l'efficacite de traitement des maladies inflammatoires
EP1670954B1 (fr)	2010-11-24	Methodes d'evaluation de risques, de prevision de survie et de traitement de l'insuffisance cardiaque et d'autres etats pathologiques a partir de polymorphismes des recepteurs adrenergiques
US20040203034A1 (en)	2004-10-14	Optimization of cancer treatment with irinotecan
US6861217B1 (en)	2005-03-01	Variation in drug response related to polymorphisms in the β2-adrenergic receptor
US20030032099A1 (en)	2003-02-13	Methods for predicting susceptibility to obesity and obesity-associated health problems
US20090018030A1 (en)	2009-01-15	Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications
WO2006063703A2 (fr)	2006-06-22	Polymorphisme a simple nucleotide (snp)
ES2361018T3 (es)	2011-06-13	Uso de polimorfismos genéticos para predecir la hepatotoxicidad inducida por fármacos.
US7807350B2 (en)	2010-10-05	Methods for predicting irinotecan toxicity
US8236497B2 (en)	2012-08-07	Methods of diagnosing cardiovascular disease
US20090192135A1 (en)	2009-07-30	Human Niemann Pick C1-Like 1 Gene (NPC1L1) Polymorphisms and Methods of Use Thereof
JP5422805B2 (ja)	2014-02-19	新規糖尿病性腎症感受性遺伝子
WO2011031769A2 (fr)	2011-03-17	Procédés pour l'évaluation des risques, le traitement, et le diagnostic d'un infarctus du myocarde
WO2006136791A1 (fr)	2006-12-28	Polymorphismes et haplotypes dans le gene p2x7 et utilisation de ceux-ci dans la determination de la susceptibilite a developper des maladies induites par l'atherosclerose
HK1105437B (en)	2012-02-24	Methods and compositions for predicting response to warfarin
HK1105437A1 (en)	2008-02-15	Methods and compositions for predicting response to warfarin
EP1756315A1 (fr)	2007-02-28	Gene de susceptibilite de l'obesite humain codant un recepteur du gout et utilisations